Početna › Difuzni veliki B-stanični limfom › Louisiana
Kliničke studije za Difuzni veliki B-stanični limfom u državi Louisiana
6 studija za Difuzni veliki B-stanični limfom traži sudionike na lokacijama u državi Louisiana.
Gradovi u državi Louisiana
Službeni tekst studije (engleski)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Mary Bird Perkins Cancer Center, Baton Rouge
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT05006716A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- CHRISTUS St. Frances Cabrini Hospital Center for Cancer Care ( Site 0184), Alexandria
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06717347A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Our Lady of the Lake Physician Group-Medical Oncology ( Site 0180), Baton Rouge
- Ochsner LSU Health - Monroe Medical Center, Family Medicine Clinic ( Site 0209), Monroe
- Ochsner Clinic Foundation ( Site 0189), New Orleans
- i još 1
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06890884Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Mary Bird Perkins Cancer Ctr, Baton Rouge
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 11. ruj 2026. · NCT06806033Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Louisiana State University Health Sciences Center, Shreveport
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT05826535DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Tulane Cancer Center Office of Clinical Research, New Orleans
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 7. tra 2023. · NCT04920617Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.